Can a better MRI scan help shrink pancreatic tumors for surgery?
NCT ID NCT06173310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special MRI technique called DCE-MRI can guide chemotherapy for people with borderline resectable pancreatic cancer. The goal is to see if this imaging method can better track tumor blood flow and help doctors decide if the treatment is working, so they can switch therapies if needed. About 50 adults with newly diagnosed, untreated pancreatic cancer will participate. The study focuses on improving imaging accuracy, not on directly treating the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DCE-MRI imaging with a portable perfusion phantom (P4 device)
- What this could lead to
- If successful, this imaging method could help doctors choose the most effective chemotherapy for each patient, potentially making more pancreatic tumors removable by surgery.
- What could go wrong
- This is a small, early-stage study focused on imaging accuracy, not treatment outcomes. The approach may not improve survival or surgical success rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Medical Center
RECRUITINGIndianapolis, Indiana, 46202, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.